FIG 6.

CCR3/CCR5 receptor antagonists restrict ZIKV persistence and viral titers in hBMECs. (A and B) hBMECs were ZIKV infected (MOI of 10) and treated with a CCR3 inhibitor (UCB35625) (20 μM), a CCR5 inhibitor (maraviroc; 20 μM), or both inhibitors twice daily to 3 dpi. The number of ZIKV-infected hBMECs was assessed at 3 dpi (A), and protein levels of ZIKV NS5 and ZIKV Env were quantified compared to GAPDH controls (B). (C and -D) Mock- and ZIKV-infected hBMECs were infected (MOI of 5) and treated with CCR3 or CCR5 inhibitors at 1 to 80 μM concentrations twice daily to 0 to 3 dpi. Treated hBMECs were quantified for the number of ZIKV-infected cells (C) and viral titers (D). Experiments were performed at least 3 times with similar results.